Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses

针对 SARS-CoV-2 和其他冠状病毒的广泛刺突蛋白茎疫苗平台

• 批准号: 10493412
• 负责人: Gary R Whittaker
• 金额: $ 23.55万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10493412
• 关键词: 2019-nCoV; ACE2; Antigens; COVID-19 vaccine; Coronavirus; Engineering; Epitopes; Escherichia coli; Goals; Human; Immune response; Immunize; Membrane; Mus; Nature; Proteins; SARS coronavirus; Serology; Structure; Subunit Vaccines; System; Testing; Transgenic Mice; Vaccination; Vaccine Antigen; Vaccine Design; Vaccines; Vesicle; Viral; Virus; base; cost effective; design; flexibility; human coronavirus; innovation; monoclonal antibody production; mouse model; novel; novel coronavirus; novel vaccines; receptor; response; vaccine development; vaccine platform; variants of concern

Project Summary/Abstract We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine platform to be applicable and effective across a wide range of existing and emerging coronaviruses. As our system is based on expression in E. coli is it expected to be cost–effective, and our stalk-based approach is specifically designed to cover a range of distinct coronaviruses. However, it is important to note that our vaccine platform is highly flexible, with the antigen able to be re-engineered rapidly in the face of a novel coronavirus that may emerge, and for which the vaccine developed in this application is not effective.

项目总结/摘要 我们建议使用基于结构的方法开发针对SARS-CoV-2的亚单位疫苗， 病毒刺突蛋白茎区的保守和功能必需结构域。我们的疫苗 该平台适用于各种现有和新出现的冠状病毒并有效。作为我们 系统是基于E.大肠杆菌，它预计将是成本效益，我们的茎为基础的方法， 专门设计用于涵盖一系列不同的冠状病毒。然而，值得注意的是，我们的疫苗 该平台具有高度灵活性，面对新型冠状病毒， 可能出现，并且在本申请中开发的疫苗对此无效。